Merck Sharp & Dohme Expands Durham Facility with $1B Investment for Vaccine Production
CompanyDeals

Merck Sharp & Dohme Expands Durham Facility with $1B Investment for Vaccine Production

Novartis' Cosentyx Approved by NMPA for Moderate to Severe Hidradenitis Suppurativa
CompanyDrug

Novartis’ Cosentyx Approved by NMPA for Moderate to Severe Hidradenitis Suppurativa

Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results
Company

Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results

Ono Pharmaceutical Licenses Ionis' Sapablursen for Global Development in Polycythemia Vera
CompanyDeals

Ono Pharmaceutical Licenses Ionis’ Sapablursen for Global Development in Polycythemia Vera

Boehringer Ingelheim One Medicine Platform Veeva Systems
CompanyDeals

Boehringer Ingelheim Launches One Medicine Platform with Veeva’s Development Cloud

Biogen Initiates TRANSCEND Study for Felzartamab in Late AMR Kidney Transplant Patients
CompanyDrug

Biogen Initiates TRANSCEND Study for Felzartamab in Late AMR Kidney Transplant Patients

MindRank Ltd Receives FDA Clearance for MRANK-106 Clinical Study in Solid Tumors
CompanyDeals

MindRank Ltd Receives FDA Clearance for MRANK-106 Clinical Study in Solid Tumors

AIM Vaccine Co. Ltd Announces Market Filing for Innovative Serum-Free Rabies Vaccine
CompanyDrug

AIM Vaccine Co. Ltd Announces Market Filing for Innovative Serum-Free Rabies Vaccine

TowardPi Medical Secures RMB500 Million in Series E Round for Ophthalmic Equipment Expansion
CompanyDeals

TowardPi Medical Secures RMB500 Million in Series E Round for Ophthalmic Equipment Expansion

WuXi XDC and AbTis Partner to Advance Antibody-Drug Conjugate Innovation
CompanyDeals

WuXi XDC and AbTis Partner to Advance Antibody-Drug Conjugate Innovation

Ascletis Pharma's ASC47 Shows Positive Results in Phase Ib Study for Weight Loss
CompanyDrug

Ascletis Pharma’s ASC47 Shows Positive Results in Phase Ib Study for Weight Loss

AstraZeneca's Imfinzi Approved by NMPA for Early-Stage NSCLC Treatment
CompanyDrug

AstraZeneca’s Imfinzi Approved by NMPA for Early-Stage NSCLC Treatment